An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer

Andel, George van; Bottomley, Andrew; Fosså, Sophie D.; Efficace, Fabio; Coens, Corneel; Guérif, S.; Kynaston, Howard; Gontero, Paolo; Thalmann, George N.; Akdaş, Atıf; D’Haese, Sven; Aaronson, Neil K.

doi:10.1016/j.ejca.2008.07.030

Cited by 403 publications

(309 citation statements)

References 11 publications

Supporting

Mentioning

288

Contrasting

Unclassified

Order By: Relevance

“…Urinary symptoms were evaluated using the urinary symptoms scale of the EORTC QLQ-PR25 questionnaire. 15 'Sexual activity' was measured with one item of the EORTC QLQ-PR25 questionnaire asking the patients, 'To what extent were you sexually active (with or without intercourse)?' Depression was assessed with the corresponding scale of the 'Hospital Anxiety and Depression Scale'.…”

Section: Variablesmentioning

confidence: 99%

Erectile dysfunction after radical prostatectomy: the impact of nerve-sparing status and surgical approach

et al. 2012

View full text Add to dashboard Cite

The core question of the study was whether the nerve-sparing status and surgical approach affected the patients' sexual life in the first year after surgery. In addition, determinants of erectile function (EF) and the extent of sexual activity were investigated. We conducted a multicentric, longitudinal study in seven German hospitals before, 3, 6 and 12 months after radical prostatectomy (RP). A total of 329 patients were asked to self-assess the symptoms associated with erectile dysfunction (ED). These symptoms were assessed using the International Index of Erectile Function and EORTC QLQ-PR25 questionnaires. A multiple regression model was used to test the influence of clinical, socio-demographic and quality-of-life-associated variables on the patients' EF 1 year after RP. Before surgery, 39% of patients had a severe ED (complete impotence). At 3, 6 and 12 months after surgery, it was 80, 79 and 71%, respectively. Although the surgical approach had no significant effect on EF, patients who had undergone nerve-sparing surgery had significantly lower ED rates. Nevertheless, 1 year after RP, 66% of these patients had severe ED. Age, nerve-sparing status and the burden of urinary symptoms had the greatest impact on the patients' EF. Regardless of nerve-sparing status and surgical approach, postsurgical improvement of EF does not mean a full convalescence of presurgical EF. Instead, it may rather reduce the degree of postsurgical ED in time. Consequently, urologists should disclose to the patient that ED is a likely side effect of RP. INTRODUCTIONIn many Western countries, prostate cancer has become the most frequently diagnosed cancer in the male population. In Germany, the current incidence is about 60 000 cases per year. 1 Since the introduction of prostate cancer screening, prostate cancer-specific incidence rates have doubled from approx. 50 per 100 000 in 1980 to approx. 100 in 2006. 2 Moreover, there has been a trend towards earlier-stage disease at presentation. 3,4 If detected in a localised state, the most common treatment for prostate cancer is radical prostatectomy (RP). RP can be performed in several ways. The classical approach is open retropubic prostatectomy. Furthermore, RP can be performed in a minimalinvasive laparoscopic way. Both surgical approaches have excellent survival outcomes. In Germany, the 5-year relative survival rate for prostate cancer is between 83 and 94%. 1 However, there are also strong side effects of RP, for example, erectile dysfunction (ED). 5 Depending on the surgical technique, patient age and other sociodemographic and clinical factors, ED rates differ a lot. Even 1 year after RP, ED occurs in about 12--83% of patients. 5--8 The current study is the first prospective multicentre study to compare the functional results of patients who underwent either radical retropubic prostatectomy (RRPE) or endoscopic extraperitoneal radical prostatectomy (EERPE). In this paper, we report data related to the patients' sexual life before (t baseline ), 3 months (t 3m ), 6 months (t 6...

show abstract

Section: Variablesmentioning

confidence: 99%

Erectile dysfunction after radical prostatectomy: the impact of nerve-sparing status and surgical approach

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) was used to assess general HRQL status (higher scores represent greater HRQL) [33]. The European Organisation for Research and Treatment of Cancer prostate cancer-specific module (QLQ-PR25) evaluated disease-specific HRQL across domains relating to urinary, bowel and treatment-related symptoms (lower scores represent less symptom severity), as well as sexual activity and sexual function (higher scores represent greater function) [34]. Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire (higher scores indicate less fatigue) [35].…”

Section: Patient-reported Outcomes (Pros)mentioning

confidence: 99%

Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen‐deprivation therapy: a randomised controlled trial

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo determine if supervised exercise minimises treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy (ADT). This is the first study to date that has investigated the potential role of exercise in preventing ADT toxicity rather than recovering from established toxicities. Patients and MethodsSixty-three men scheduled to receive ADT were randomly assigned to a 3-month supervised exercise programme involving aerobic and resistance exercise sessions commenced within 10 days of their first ADT injection (32 men) or usual care (31 men). The primary outcome was body composition (lean and fat mass). Other study outcomes included bone mineral density, physical function, blood biomarkers of chronic disease risk and bone turnover, general and prostate cancer-specific quality of life, fatigue and psychological distress. Outcomes were compared between groups using analysis of covariance adjusted for baseline values. ResultsCompared to usual care, a 3-month exercise programme preserved appendicular lean mass (P = 0.019) and prevented gains in whole body fat mass, trunk fat mass and percentage fat with group differences of −1.4 kg (P = 0.001), −0.9 kg (P = 0.008) and −1.3% (P < 0.001), respectively. Significant between-group differences were also seen favouring the exercise group for cardiovascular fitness (peak oxygen consumption 1.1 mL/kg/min, P = 0.004), muscular strength (4.0-25.9 kg, P ≤ 0.026), lower body function (-1.1 s, P < 0.001), total cholesterol: high-density lipoprotein-cholesterol ratio (-0.52, P = 0.028), sexual function (15.2, P = 0.028), fatigue (3.1, P = 0.042), psychological distress (-2.2, P = 0.045), social functioning (3.8, P = 0.015) and mental health (3.6-3.8, P ≤ 0.022). There were no significant group differences for any other outcomes. ConclusionCommencing a supervised exercise programme involving aerobic and resistance exercise when initiating ADT significantly reduced treatment toxicity, while improving social functioning and mental health. Concurrent prescription of supervised exercise when initiating ADT is therefore advised to minimise morbidity associated with severe hypogonadism.

show abstract

“…21 This 25-item questionnaire assesses HRQOL of prostate cancer patients over the past week (20 items) or the last 4 weeks (5 items). It comprises two functional scales (sexual activity and sexual functioning) and four symptom scales (urinary, bowel, hormonal treatment-related, incontinence aid).…”

Section: European Organization For Research and Treatment Of Cancer Qmentioning

confidence: 99%

Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population

Vigneault

Savard

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: This study aims to empirically validate the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC), a measure of health-related quality of life for prostate cancer patients. Methods: 251 participants completed a battery of self-report scales including the FrenchCanadian version of the EPIC, after having received radiation therapy or radical prostatectomy for prostate cancer. Results: The internal consistency for the urinary incontinence, bowel, and sexual domains of the EPIC-26 was high (Cronbach's alpha coefficients from .80 to .92), while coefficients for the urinary irritation/obstruction (.59) and hormonal (.67) domains were lower. Item-total correlations (rs=.15 to .85), and temporal stability (rs=.72 to .93) generally supported the reliability of the instrument. The 5-factor structure of the EPIC-26 was confirmed for the most part. The construct validity of the instrument was also supported by high correlations obtained between each domain and measures assessing similar constructs (rs=-.56 to .83). The EPIC also showed an excellent sensitivity to change with significant differences obtained on EPIC scores (all ps<.05) between pre-and post-prostate cancer treatment. Conclusions:The psychometric qualities of the French-Canadian version of the EPIC are well supported, thus providing a valid tool to assess HRQOL in prostate cancer patients.

show abstract

An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer

Cited by 403 publications

References 11 publications

Erectile dysfunction after radical prostatectomy: the impact of nerve-sparing status and surgical approach

Erectile dysfunction after radical prostatectomy: the impact of nerve-sparing status and surgical approach

Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen‐deprivation therapy: a randomised controlled trial

Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population

Contact Info

Product

Resources

About